Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 4
2004 5
2005 3
2006 2
2007 2
2008 4
2009 4
2010 1
2011 1
2012 5
2013 5
2014 3
2015 4
2016 5
2017 4
2018 6
2019 4
2020 5
2021 3
2022 11
2023 9
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HB, Poetschger U, Schwinger W, Meisel R, Schuster FR, Döring M, Ambros PF, Queudeville M, Fuchs J, Warmann SW, Schäfer J, Seitz C, Schlegel P, Brecht IB, Holzer U, Feuchtinger T, Simon T, Schulte JH, Eggert A, Teltschik HM, Illhardt T, Handgretinger R, Lang P. Flaadt T, et al. Among authors: lode hn. J Clin Oncol. 2023 Jun 10;41(17):3135-3148. doi: 10.1200/JCO.22.01630. Epub 2023 Feb 28. J Clin Oncol. 2023. PMID: 36854071 Free PMC article. Clinical Trial.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: lode hn. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Rouaen JRC, Salerno A, Shai-Hee T, Murray JE, Castrogiovanni G, McHenry C, Jue TR, Pham V, Bell JL, Poursani E, Valli E, Cazzoli R, Damstra N, Nelson DJ, Stevens KLP, Chee J, Slapetova I, Kasherman M, Whan R, Lin F, Cochran BJ, Tedla N, Veli FC, Yuksel A, Mayoh C, Saletta F, Mercatelli D, Chtanova T, Kulasinghe A, Catchpoole D, Cirillo G, Biro M, Lode HN, Luciani F, Haber M, Gray JC, Trahair TN, Vittorio O. Rouaen JRC, et al. Among authors: lode hn. Nat Commun. 2024 Dec 12;15(1):10462. doi: 10.1038/s41467-024-54689-x. Nat Commun. 2024. PMID: 39668192 Free PMC article.
Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression.
Meissner B, Lang P, Bader P, Hoenig M, Müller I, Meisel R, Greil J, Sauer MG, Metzler M, Corbacioglu S, Burkhardt B, Wölfl M, Strahm B, Kafa K, Basu O, Lode HN, Gruhn B, Cario H, Ozga AK, Zimmermann M, Jarisch A, Beier R. Meissner B, et al. Among authors: lode hn. Bone Marrow Transplant. 2024 May;59(5):587-596. doi: 10.1038/s41409-024-02219-0. Epub 2024 Feb 7. Bone Marrow Transplant. 2024. PMID: 38326567 Free PMC article.
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.
Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, Kloth C, Stamopoulou A, Moritz T, Lode HN, Siebert N, Blasczyk R, Goudeva L, Schambach A, Köhl U, Eiz-Vesper B, Esser R. Glienke W, et al. Among authors: lode hn. Front Immunol. 2022 Mar 24;13:839783. doi: 10.3389/fimmu.2022.839783. eCollection 2022. Front Immunol. 2022. PMID: 35401506 Free PMC article.
Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells.
Riess C, Del Moral K, Fiebig A, Kaps P, Linke C, Hinz B, Rupprecht A, Frank M, Fiedler T, Koczan D, Troschke-Meurer S, Lode HN, Engel N, Freitag T, Classen CF, Maletzki C. Riess C, et al. Among authors: lode hn. Cell Death Dis. 2022 Jun 18;13(6):555. doi: 10.1038/s41419-022-05006-1. Cell Death Dis. 2022. PMID: 35717443 Free PMC article.
Rare clival localization of an eosinophilic granuloma: illustrative case.
Weidemeier ME, Fleck S, Hosemann W, Vogelgesang S, Ehlert K, Lode HN, Schroeder HWS. Weidemeier ME, et al. Among authors: lode hn. J Neurosurg Case Lessons. 2023 Jun 19;5(25):CASE22490. doi: 10.3171/CASE22490. Print 2023 Jun 19. J Neurosurg Case Lessons. 2023. PMID: 37354435 Free PMC article.
89 results